The Splanchnic Circulation in Cirrhosis

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 156-163

  Bosch, Jaime ^a   García Pagán, Juan Carlos ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cirrhosis; Hypertension; Renal dysfunction; Splanchnic hemodynamics; Vascular system

Indexed keywords

EID: 84889388347     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch12     Document Type: Chapter

References (73)

1. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32 (1 SUPPL.):141-56.
2. VorobioffJ, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-G57.
3. VorobioffJ, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984; 87:1120-6.
4. Sikuler E, Groszmann RJ. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 1986; 250: G205-G212.
5. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985; 248: G618-G625.
6. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6:287-98.
7. Benoit JN, Barrowman JA, Harper SL, Kvietys PR, Granger DN. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol 1984; 247: G486-G493.
8. Gomis R, Fernández-Alvarez J et al. Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation. Hepatology 1994; 19:1257-61.
9. Benoit JN, Zimmerman B, Premen AJ, Go VL, Granger DN. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986; 251: G674-G677.
10. Kravetz D, Bosch J, Arderiu MT et al. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. Am J Physiol 1988; 254: G322-G328.
11. Sikuler E, Groszmann RJ. Hemodynamic studies in longand short-term portal hypertensive rats: the relation to systemic glucagon levels. Hepatology 1986; 6:414-18.
12. Genecin P, Polio J, Groszmann RJ. Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension. Am J Physiol 1990; 259: G498-G503.
13. Thomas SH, Joh T, Benoit JN. Role of bile acids in splanchnic hemodynamic response to chronic portal hypertension. Dig Dis Sci 1991; 36:1243-8.
14. Fernández M, Casadevall M, Schuligoi R et al. Neonatal capsaicin treatment does not prevent splanchnic vasodilatation in portal-hypertensive rats. Hepatology 1994; 20:1609-14.
15. Lee SS, Sharkey KA. Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats. Am J Physiol 1993; 264: G868-G873.
16. Hori N, Okanoue T, Sawa Y, Kashima K. Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats. J Hepatol 1997; 26:1111-19.
17. Batkai S, Jarai Z, Wagner JA et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7:827-32.
18. Ros J, Clària J, To-Figueras J et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122:85-93.
19. Pizcueta MP, Piqué JM, Bosch J, Whittle BJ, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992; 105:184-90.
20. Pizcueta P, Piqué JM, Fernandez M et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103:1909-15.
21. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992; 103:235-9.
22. Castro A, Jiménez W, Clària J et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology 1993; 18:367-72.
23. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992; 16:1043-8.
24. Sieber CC, López-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993; 104:1750-4.
25. Guarner C, Soriano G, Tomas A et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139-43.
26. Battista S, Bar F, Mengozzi G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997; 26:75-80.
27. Sarela AI, Mihaimeed FM, Batten JJ, Davidson BR, Mathie RT. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 1999; 44:749-53.
28. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998; 28:1467-73.
29. Heinemann A, Wachter CH, Fickert P, Trauner M, Stauber RE. Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. Hepatology 1998; 28:646-54.
30. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223-33.
31. Niederberger M, Ginès P, Martin PY et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 1996; 24:947-51.
32. Martin PY, Xu DL, Niederberger M et al. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996; 270: F494-F499.
33. Wiest R, Hori N, Cadelina G, Das S, Groszmann RJ. Increased nitric oxide release in response to vasoconstrictors in the superior mesenteric arterial bed of cirrhotic rats. Hepatology 1997; 26:390A.
34. Martin PY, Ohara M, Ginès P et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998; 101:235-42.
35. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276: G1043-G1051.
36. Iwakiri Y, Tsai MH, McCabe TJ et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol 2002; 282: H2084-H2090.
37. Garcia-Cardena G, Fan R, Shah V et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998; 392:821-4.
38. Shah V, Wiest R, Garcia-Cardena G, Cadelina G, Groszmann RJ, Sessa WC. Hsp90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999; 277: G463-G468.
39. Stroes E, Kastelein J, Cosentino F et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99:41-6.
40. López-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996; 23:1616-21.
41. López-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108:761-7.
42. Garcia-Pagan JC, Fernández M, Bernadich C et al. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am J Physiol 1994; 267: G984-G990.
43. Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1074-G1081.
44. Smith WL. The eicosanoids and their biochemical mechanisms of action. Biochem J 1989; 259:315-24.
45. Sitzmann JV, Li SS, Lin PW. Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension. J Surg Res 1989; 47:208-11.
46. Hamilton G, Phing RC, Hutton RA, Dandona P, Hobbs KE. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology 1982; 2:236-42.
47. Guarner C, Soriano G, Such J et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102:303-9.
48. Potenza MA, Botrugno OA, De Salvia MA et al. Endothelial COX-1 and-2 differentially affect reactivity of MVB in portal hypertensive rats. Am J Physiol Gastrointest Liver Physiol 2002; 283: G587-G594.
49. Bruix J, Bosch J, Kravetz D, Mastai R, Rodés J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88:430-5.
50. Sitzmann JV, Li SS, Adkinson NF. Evidence for role of prostacyclin as a systemic hormone in portal hypertension. Surgery 1991; 109:149-53.
51. Wu YP, Li SS, Campbell KA, Sitzmann JV. Modulation of splanchnic vascular sensitivity to angiotensin II. Surgery 1991; 110:162-8.
52. Piqué JM, Leung FW, Kitahora T, Sarfeh IJ, Tarnawski A, Guth PH. Gastric mucosal blood flow and acid secretion in portal hypertensive rats. Gastroenterology 1988; 95:727-33.
53. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: F181-F191.
54. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107:1491-5.
55. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J Biol Chem 1996; 271:33157-60.
56. Graupera M, Garcia-Pagan JC, Abraldes JG et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003; 37:172-81.
57. Graupera M, Garcia-Pagan JC, Pares M et al. Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 2003; 39: 521.
58. Clària J, Jiménez W, Ros J et al. Increased nitric oxidedependent vasorelaxation in aortic rings of cirrhotic rats with ascites. Hepatology 1994; 20:1615-21.
59. Heinemann A, Stauber RE. Vasodilator responses to nitric oxide are enhanced in mesenteric arteries of portal hypertensive rats. Eur J Clin Invest 1996; 26:824-6.
60. Albillos A, Rossi I, Cacho G et al. Enhanced endotheliumdependent vasodilation in patients with cirrhosis. Am J Physiol 1995; 268: G459-G464.
61. Fernández M, Garcia-Pagan JC, Casadevall M et al. Acute and chronic cyclooxygenase blockage in portalhypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology 1996; 110:1529-35.
62. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodés J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypersensitive mice. Gastroenterology 2004; 126:886-94.
63. Sieber CC, Sumanovski LT, Stumm M, van der KM, Battegay E. In vivo angiogenesis in normal and portal hypertensive rats: role of basic fibroblast growth factor and nitric oxide. J Hepatol 2001; 34:644-50.
64. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 1992; 263: G544-G550.
65. Cummings SA, Groszmann RJ, Kaumann AJ. Hypersensitivity of mesenteric veins to 5-hydroxytryptamine-and ketanserininduced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 1986; 89:501-13.
66. Kaumann AJ, Morgan JS, Groszmann RJ. ICI 169,369 selectively blocks 5-hydroxytryptamine-2 receptors and lowers portal pressure in portal hypertensive rats. Gastroenterology 1988; 95:1601-6.
67. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985; 5:97-101.
68. Kravetz D, Bosch J, Arderiu M, Pilar PM, Rodés J. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portalsystemic shunting. Hepatology 1989; 9:808-14.
69. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21:1238-47.
70. Bathal PS, Grossmann HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985; 1:325-9.
71. Kaneda K, Ekataksin W, Sogawa M, Matsumura A, Cho A, Kawada N. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 1998; 27:735-47.
72. Zhang JX, Pegoli W, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 1994; 266: G624-G632.
73. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993; 213:815-23.